Abstracts tagged "fractures"

Abstract Number: 336 • 2016 ACR/ARHP Annual Meeting
The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab
DL Kendler¹, A Chines², ML Brandi³, S Papapoulos⁴, EM Lewiecki⁵, J-Y Reginster⁶, C Roux⁷, M Munoz Torres⁸, A Wang² and HG Bone⁹, ¹University of British Columbia, Vancouver, BC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³University of Florence, Florence, Italy, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁶University of Liège, Liège, Belgium, ⁷Paris Descartes University, Paris, France, ⁸Hospital Universitario San Cecilio, Granada, Spain, ⁹Michigan Bone and Mineral Clinic, Detroit, MI
Background/Purpose: Osteoporosis is a common, progressive condition leading to increased bone fragility and susceptibility to fracture. Although osteoporosis therapy decreases fracture risk, fractures while on…
Abstract Number: 337 • 2016 ACR/ARHP Annual Meeting
Denosumab Treatment for 10 Years in Postmenopausal Women with Osteoporosis Was Associated with Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-Predicted Probability
E Siris¹, N Pannacciulli², PD Miller³, EM Lewiecki⁴, R Chapurlat⁵, E Jódar-Gimeno⁶, NS Daizadeh², RB Wagman² and JA Kanis⁷, ¹Columbia University Medical Center, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³Colorado Center for Bone Research, Lakewood, CO, ⁴New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁵Hôpital Edouard Herriot, Lyon, France, ⁶Hospital Universitario Quirónsalud Madrid, Madrid, Spain, ⁷University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Denosumab is approved for treating postmenopausal women with osteoporosis at high risk for fracture. The placebo-controlled FREEDOM trial and its active-treatment Extension investigated the…
Abstract Number: 345 • 2016 ACR/ARHP Annual Meeting
The Relationship Between Anti-Cyclic Citrullinated Peptide (anti-CCP) Levels and Bone Mineral Density (BMD) or Fragility Fracture in Patients with Rheumatoid Arthritis (RA)
Tien-Tsai Cheng^1,2, Yin-Chou Chen^1,2, Shan-Fu Yu^1,2, Han-Ming Lai^1,2, Ben Yu-Jih Su^1,2, Fu-Mei Su^2,3, Wen-Chan Chiu^1,2, Chung-Yuan Hsu^1,4, Jia-Feng Chen¹ and Chi-Hua Ko¹, ¹Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan, ²Chang Gung University College of Medicine, Kaohsiung, Taiwan, ³Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan, ⁴Division of Rheumatology, Allergy, and Immunology, Chang Gung University College of Medicine, Kaohsiung, Taiwan
Background/Purpose: To explore the relationship of anti-CCP levels with BMD or fragility fracture in patients with RA Methods: This is a prospective cross sectional study.…
Abstract Number: 895 • 2016 ACR/ARHP Annual Meeting
Incidence of Osteoporotic Mayor Fractures in a Cohort of Patients with Polymyalgia Rheumatica
Luciano Enrique Pompermayer¹, Ignacio Javier Gandino¹, Maximiliano José Martinez¹, Florencia Beatriz Mollerach¹, Marina Scolnik², Javier Rosa¹ and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory disease associated with older age and long term use of glucocorticoids. As such a high incidence of osteoporosis…
Abstract Number: 1023 • 2016 ACR/ARHP Annual Meeting
Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis
F Cosman¹, DB Crittenden², JD Adachi³, N Binkley⁴, E Czerwinski⁵, S Ferrari⁶, LC Hofbauer⁷, E Lau⁸, EM Lewiecki⁹, A Miyauchi¹⁰, CAF Zerbini¹¹, CE Milmont², L Chen², J Maddox², PD Meisner¹², C Libanati¹² and A Grauer², ¹Helen Hayes Hospital, West Haverstraw, and Columbia University, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³McMaster University, Hamilton, ON, Canada, ⁴University of Wisconsin–Madison Osteoporosis Clinical Center and Research Program, Madison, WI, ⁵Krakow Medical Center, Krakow, Poland, ⁶Geneva University Hospital, Geneva, Switzerland, ⁷Division of Endocrinology, Diabetes, and Bone Diseases, TU Dresden Medical Center, Dresden, Germany, ⁸Center for Clinical and Basic Research, Hong Kong, China, ⁹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ¹⁰Miyauchi Medical Center, Osaka, Japan, ¹¹Centro Paulista de Investigação Clinica, São Paulo, Brazil, ¹²UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab (Romo) is an investigational bone-forming monoclonal antibody that binds sclerostin and has a dual effect, increasing bone formation and decreasing bone resorption. Here,…
Abstract Number: 346 • 2015 ACR/ARHP Annual Meeting
Autoantibodies to Osteoprotegerin Are Independently Associated with Low Hip Bone Mineral Density and Increased Fractures in Axial Spondyloarthritis
Sizheng Zhao^1,2, Barbara Hauser³, Micaela Visconti³, Philip L. Riches³, Stuart H. Ralston³ and Nicola Goodson^1,2, ¹Musculoskeletal Biology I, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ²Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, ³Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis. However the underlying causes are incompletely understood. Osteoprotegerin (OPG) is a bone protective protein that acts as…
Abstract Number: 371 • 2015 ACR/ARHP Annual Meeting
New Vertebral Fractures after Vertebroplasty: Two Year Results from a Randomised Placebo-Controlled Trial
Margaret P. Staples¹, B Matthew Howe², Michael Ringler², Peter Mitchell³, Chris Wriedt⁴, John Wark⁵, Peter Ebeling⁶, Richard Osborne⁷, David Kallmes² and Rachelle Buchbinder⁸, ¹Monash Department of Clinical Epidemiology, Cabrini Institute and Monash University, Malvern, Australia, ²Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN, ³Department of Radiology, The University of Melbourne, Royal Melbourne Hospital, Melbourne, Australia, ⁴MIA Radiology, Melbourne, Australia, ⁵Department of Medicine, The University of Melbourne, Royal Melbourne Hospital, Melbourne, Australia, ⁶Department of Medicine, Monash University, Monash Medical Centre, Melbourne, Australia, ⁷Public Health Innovation, Deakin University, Melbourne, Australia, ⁸Monash Department of Clinical Epidemiology, Cabrini Institute and Monash University, Melbourne, Australia
Background/Purpose: We previously reported the results of a randomized participant and outcome assessor blinded controlled trial that found no beneficial effect of vertebroplasty (VP) over…
Abstract Number: 382 • 2015 ACR/ARHP Annual Meeting
Twelve Months after Osteoporosis Associated Fracture – Has Adequate Therapy Been Initiated?
Christoph Hemmeler¹, Sabrina Morell², Paul Hasler¹ and Thomas Gross², ¹Rheumatology, Kantonsspital Aarau, Aarau, Switzerland, ²Traumatology, Kantonsspital Aarau, Aarau, Switzerland
Background/Purpose: Evidence shows that of ten patients taking medication against osteoporosis one will avoid subsequent fractures, decreasing the risk by > 50 %. On the…
Abstract Number: 2084 • 2015 ACR/ARHP Annual Meeting
Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Modulates Bone Resorption in Inflammatory Arthritis and Fracture Repair
Yahui Grace Chiu¹, Tzong-Ren Sheu², Jinbo Li³, Dongge Li⁴, Michael Thullen², Brendan Boyce⁵, Christopher T. Ritchlin⁶ and Javier Rangel-Moreno⁷, ¹Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ²Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ³Pathology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵University of Rochester, Rochester, NY, ⁶Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁷Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Osteoclasts (OC) direct pathologic bone resorption in osteoporosis and inflammatory arthritis. We previously demonstrated that DC-STAMP (Dendritic Cell-Specific Transmembrane protein), a 7-pass transmembrane protein,…
Abstract Number: 2165 • 2015 ACR/ARHP Annual Meeting
Awareness and Reasons for Lack of Post-Fracture Osteoporosis Therapy: A Survey of Post-Menopausal Women
Denise Boudreau¹, Onchee Yu¹, Akhila Balasubramanian², Jane Grafton¹, Heidi Wirtz³, Andreas Grauer³, D. Barry Crittenden³ and Delia Scholes¹, ¹Group Health Research Institute, Seattle, WA, ²Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: Osteoporotic fractures cause patient morbidity and increase risk for future fracture. Effective drug therapies for osteoporosis (OP) are available, yet only a minority of…
Abstract Number: 2210 • 2015 ACR/ARHP Annual Meeting
Immunological Dysregulation and Inadequate Hypoxia Adaptation – HIF-Stabilization As Possible Prevention of Fracture Healing Disorders in RA or Immune-Suppressed Patients
Annemarie Lang^1,2,3, Sarah Fuegener², Paula Hoff^1,2, Katharina Schmidt-Bleek⁴, Timo Gaber^1,2 and Frank Buttgereit², ¹German Rheumatism Research Center (DRFZ), Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ³Berlin-Brandenburg School of Regenerative Therapies (BSRT), Berlin, Germany, ⁴Julius Wolff Institut, Charité University Medicine, Berlin, Germany
Background/Purpose: Patients suffering from rheumatoid arthritis (RA) are often affected by fracture-healing complications such as increased fracture healing time or non-unions. There is not much…
Abstract Number: 3173 • 2015 ACR/ARHP Annual Meeting
Premature Mortality Due to Fractures in a Population-Based Prospective Cohort Study of 238,673 Older Women and Men
Lyn March¹, Weiwen Chen², Judy M Simpson³, Fiona Blyth⁴ and Jacqueline Center², ¹Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ²Endocrinology, Osteoporosis & Bone Biology Garvan Institute of Medical Research, St Vincent's Clinical School, UNSW, Darlinghurst, Australia, ³Statistics, University of Sydney School of Public Health, Sydney, Australia, ⁴Concord Clinical School University of Sydney and Sax Institute, Sydney, Australia
Background/Purpose: Osteoporotic (OP) fractures and falls are a growing global problem as the population ages. One third of all falls related deaths are attributable to…
Abstract Number: 50 • 2014 ACR/ARHP Annual Meeting
Incidence and Risk Factors for Osteoporotic Vertebral Fracture in Low-Income Community-Dwelling Elderly: A Population-Based Prospective Cohort Study in Brazil. the São Paulo Ageing & Health (SPAH) Study
Diogo S. Domiciano¹, Luana G. Machado², Jaqueline B. Lopes², Valéria Caparbo², Liliam Takayama², Ricardo M. Oliveira³ and Rosa M. R. Pereira⁴, ¹Rheumatology, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³RDO Diagnosticos Medicos, São Paulo, Brazil, ⁴Reumatologia, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil
Background/Purpose: Vertebral fractures are associated with increased future fracture risk and mortality. No data on incidence of osteoporotic vertebral fracture have been reported in low-income…
Abstract Number: 25 • 2014 ACR/ARHP Annual Meeting
DC-STAMP Modulates Osteoblast Differentiation and Regulates Bone Repair
Yahui Grace Chiu¹, Tzong-Ren Sheu², Jinbo Li³, Dongge Li¹, Michael Thullen², Brendan Boyce⁴, Edward Puzas² and Christopher T. Ritchlin⁵, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ³Pathology, University of Rochester, Rochester, NY, ⁴Pathology, University of Rochester, Rocehster, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose Patients with osteoporosis and the elderly have an increased risk of bone fracture. Currently, no biomarker is available to assess bone healing status in…
Abstract Number: 2471 • 2014 ACR/ARHP Annual Meeting
Effect of Teriparatide in Patients with Osteoporosis and Rheumatoid Arthritis
Robin Dore¹, Kenneth G. Saag², Guillermo Valenzuela³, Kathleen Taylor⁴, Qiu He⁴, Jahangir Alam⁴ and Kelly D. Krohn⁵, ¹University of California, Los Angeles, CA, ²Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ³Integral Rheumatology and Immunology Specialists, Plantation, FL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵DC 5208, Eli Lilly and Company, LLC, Indianapolis, Indiana, Indianapolis, IN
Background/Purpose: A common complication in rheumatoid arthritis (RA) is osteoporosis (OP) with increased incidence of fragility fractures. RA is the only disease specifically included…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].